Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeVRTXVertex Pharmaceuticals$445.20+0.9%$454.50$377.85▼$519.88$114.33B0.421.42 million shs1.11 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceVRTXVertex Pharmaceuticals0.00%+0.10%-0.39%-8.98%-5.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationVRTXVertex Pharmaceuticals4.6885 of 5 stars3.35.00.03.33.32.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceVRTXVertex Pharmaceuticals 2.54Moderate Buy$511.6214.92% UpsideCurrent Analyst Ratings BreakdownLatest VRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025VRTXVertex PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$550.006/20/2025VRTXVertex PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$464.00 ➝ $460.006/17/2025VRTXVertex PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetSector Perform ➝ Sector Perform$423.00 ➝ $420.005/23/2025VRTXVertex PharmaceuticalsErste Group BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/7/2025VRTXVertex PharmaceuticalsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Peer Perform5/6/2025VRTXVertex PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/6/2025VRTXVertex PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/6/2025VRTXVertex PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/6/2025VRTXVertex PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$450.00 ➝ $442.005/6/2025VRTXVertex PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$420.00 ➝ $423.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookVRTXVertex Pharmaceuticals$11.02B10.37N/AN/A$63.72 per share6.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateVRTXVertex Pharmaceuticals-$535.60M-$3.92N/A25.43N/A-8.91%-3.36%-2.42%7/30/2025 (Estimated)Latest VRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025VRTXVertex Pharmaceuticals$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioVRTXVertex Pharmaceuticals0.012.652.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipVRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipVRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableVRTXVertex Pharmaceuticals6,100256.80 million256.28 millionOptionableVRTX HeadlinesRecent News About These CompaniesVRTX Vertex Pharmaceuticals Incorporated - Seeking Alpha2 hours ago | seekingalpha.comVertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?June 30 at 9:31 AM | zacks.comNew York State Teachers Retirement System Trims Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 30 at 6:41 AM | marketbeat.comAmalgamated Bank Increases Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 30 at 6:32 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Allspring Global Investments Holdings LLCJune 30 at 4:47 AM | marketbeat.comH.C. Wainwright Reaffirms Vertex Buy Rating After ADA Conference ResultsJune 29 at 2:18 PM | msn.comGoodman Advisory Group LLC Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 29 at 6:41 AM | marketbeat.comTBH Global Asset Management LLC Invests $297,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 29 at 6:24 AM | marketbeat.comPerpetual Ltd Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 29 at 4:30 AM | marketbeat.comGAMMA Investing LLC Raises Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 29 at 3:03 AM | marketbeat.comLittle House Capital LLC Purchases 1,573 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 28 at 8:17 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Sumitomo Mitsui Trust Group Inc.June 28 at 8:17 AM | marketbeat.comHeirloom Wealth Management Grows Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 28 at 7:12 AM | marketbeat.comMirae Asset Global Investments Co. Ltd. Has $69.55 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 28 at 5:43 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Sequoia Financial Advisors LLCJune 28 at 4:11 AM | marketbeat.comGolden State Wealth Management LLC Acquires 567 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 28 at 4:04 AM | marketbeat.comMoran Wealth Management LLC Sells 29,300 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 28 at 3:49 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives $513.14 Consensus Price Target from BrokeragesJune 28 at 3:04 AM | americanbankingnews.comEquities Analysts Offer Predictions for VRTX Q3 EarningsJune 28 at 2:08 AM | americanbankingnews.comVertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New DrugJune 27 at 10:19 AM | insidermonkey.comPhilip James Wealth Mangement LLC Purchases New Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 27 at 8:17 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRTX Company DescriptionsVertex Pharmaceuticals NASDAQ:VRTX$445.20 +3.90 (+0.88%) As of 04:00 PM EasternVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
